|
Thursday 14th September 2023 |
Text too small? |
Cannasouth Limited (NZX: CBD ) has exported to Australia its first commercial shipment of its high-purity cannabidiol (CBD) isolate, a cannabis-based, active pharmaceutical ingredient (API). This is a first for Aotearoa New Zealand’s medicinal cannabis industry.
This CBD isolate was manufactured in New Zealand to PIC/s Good Manufacturing Practice (GMP) standards and verified by the Medicinal Cannabis Agency. This first shipment is the forerunner of greater volumes of API exports for the local industry, signalling the demand for high-quality, GMP certified cannabis-based APIs on the international stage.
This signals the next growth phase for Cannasouth and the medicinal cannabis industry.
-ENDS-
No comments yet
MCY - Mercury opens $220m geothermal expansion
PYS - PaySauce undertakes Minimum Holding buyback
March 17th Morning Report
Meridian Energy monthly operating report for February 2026
MCY - Mercury considers Green Bond offer
March 16th Morning Report
Metro Performance Glass FY26 Market Update
Devon Funds Morning Note - 13 March 2026
Devon Funds Morning Note - 12 March 2026
TCM - Financial Model